Can you take zinc with acid reflux medicine?
Answers from top 5 papers
More filters
| Papers (5) | Insight |
|---|---|
69 Citations | The results of this study suggest that zinc absorption in humans can be improved by complexing zinc with picolinic acid. |
54 Citations | It is concluded that in persistent diarrhoea there is depletion of zinc with the progression of disease and oral zinc administration can improve the zinc status. |
56 Citations | Gastric acid was also reduced after ranitidine, but not after cimetidine (500 mg) administration, suggesting that gastric acid secretion plays a role in the regulation of zinc absorption in man. |
87 Citations | Zinc absorption can be predicted from dietary zinc and phytate after allowing for dietary equilibration. |
01 Dec 2005 19 Citations | Zinc absorption in humans could be improved by zinc complexation with gluconate. |
My columns
Related Questions
See what other people are reading
Can personal lubricant formulations be used as a preventive measure against HIV transmission during sexual intercourse?
4 answers
Personal lubricant formulations have shown potential as preventive measures against HIV transmission during sexual intercourse. Studies have explored the use of lubricants containing anti-viral agents like carrageenan and Dapivirine to reduce the propagation of HIV. Vaginal formulations, including gels, rings, and films, have been developed to release drugs like Dapivirine, Tenofovir, and Maraviroc upon contact with the vaginal medium, aiming to protect women from HIV infection. Innovative delivery devices, such as nonwoven vaginal devices, have been designed to improve gel retention and reduce leakage, showing promising acceptability and performance for vaginal drug delivery. These advancements highlight the potential of lubricant-based formulations in providing protection against HIV transmission, emphasizing the importance of further research and development in this field.How does rezafungin compare to other antifungal drugs in terms of efficacy and safety?10 answers
Rezafungin, a novel echinocandin, has been compared to other antifungal drugs, particularly caspofungin, in terms of efficacy and safety across various studies. In the Phase 3 ReSTORE trial, rezafungin demonstrated noninferiority to caspofungin in treating candidemia and invasive candidiasis, with similar efficacy outcomes in immunocompromised patients and across different renal function categories. This is further supported by a patient-level meta-analysis from the STRIVE and ReSTORE trials, which showed comparable 30-day all-cause mortality rates and mycological response between rezafungin and caspofungin, alongside a similar safety profile.
Rezafungin's once-weekly dosing regimen is a significant advantage over daily dosing required by other echinocandins, potentially improving patient compliance without compromising safety or efficacy. Its pharmacokinetic profile, characterized by a long half-life, allows for this less frequent dosing while maintaining effectiveness.
In terms of safety, rezafungin has shown a low potential for drug-drug interactions, a common limitation among antifungal agents. This attribute enhances its suitability for patients undergoing complex treatment regimens, as demonstrated in studies assessing interactions with common medications. Adverse events associated with rezafungin were generally mild and comparable to those observed with caspofungin.
Rezafungin's in vitro activity against a wide range of fungal pathogens, including multidrug-resistant strains, is comparable to or exceeds that of other echinocandins and antifungals, suggesting a broad utility in treating invasive fungal infections. Its efficacy against Candida spp., including fluconazole-resistant strains, and Aspergillus spp., positions rezafungin as a potent option in the antifungal treatment landscape.
Overall, rezafungin compares favorably to other antifungal drugs, offering a combination of effective antifungal activity, safety, and a more convenient dosing schedule that could benefit a wide range of patients.How effective is rezafungin in treating fungal infections compared to other antifungal medications?9 answers
Rezafungin, a next-generation echinocandin, has demonstrated promising efficacy in treating fungal infections, particularly candidemia and invasive candidiasis, compared to other antifungal medications. Its once-weekly dosing regimen, due to a long half-life of around 133 hours, offers a significant advantage in terms of patient compliance and administration convenience. In clinical trials, rezafungin showed non-inferiority to caspofungin, a well-established echinocandin, in terms of 30-day all-cause mortality (ACM) and global response at Day 14, with comparable safety profiles. This was further supported by patient-level meta-analyses from the STRIVE and ReSTORE trials, which also highlighted rezafungin's efficacy with similar 30-day ACM rates and safety to caspofungin.
Rezafungin's in vitro activity against a wide range of fungal pathogens, including Candida spp., Aspergillus spp., and Pneumocystis spp., has been extensively documented. It has shown potent activity against Candida spp., including multidrug-resistant strains like Candida auris, and Aspergillus spp., with a broad spectrum of activity that is comparable or superior to other echinocandins like caspofungin, micafungin, and anidulafungin. Moreover, rezafungin has demonstrated a low potential for drug-drug interactions, which is a significant advantage over other antifungal agents that often have severe drug-drug interactions limiting their use.
Clinical outcomes in patients with renal impairment also indicate that rezafungin's efficacy is comparable across different levels of renal function, offering a therapeutic option for a broader patient population. Additionally, rezafungin has been effective in treating fungal infections in immunocompromised patients, a group that typically presents a challenge in antifungal therapy.
In summary, rezafungin has shown to be an effective antifungal agent with a favorable safety profile, comparable efficacy to other echinocandins, and advantages in dosing frequency and drug-drug interaction potential, making it a valuable addition to the antifungal therapeutic arsenal.What is the impact of boiling ginger on secondary metabolites like gingerol and shogaol?5 answers
Boiling ginger has a significant impact on secondary metabolites like gingerol and shogaol. The process of boiling ginger rhizomes alters the composition of these active compounds due to the influence of temperature. Studies have shown that the thermal processing of ginger can lead to changes in the content and transformation of compounds, affecting the overall composition of the plant matrix. Additionally, the metabolism of ginger compounds like gingerols and shogaols in humans has been studied, revealing that these components undergo ketone reduction and cysteine conjugation pathways, producing various metabolites with potential health benefits. Therefore, boiling ginger can impact the levels and types of secondary metabolites present, potentially influencing the therapeutic properties of the plant.Has there been juice made from fruit powder,water and sugar?5 answers
Yes, juice has been made from fruit powder, water, and sugar according to the research papers provided. Different methods have been employed to create juice powder, such as drying in foam mat, spray drying process, and agitating and uniformly mixing raw materials. These methods involve steps like preparing fruit concentrate, converting it to powders, encapsulating, and blending with sugar and other ingredients. The juice powder may contain various components like water-soluble lutein ester powder, fruit powder, granulated sugar, sugar alcohol, and food additives. The resulting juice powder mixes are rich in nutrients, have health benefits, and can be stored for extended periods.Chicken preservation by using coacervates?5 answers
Chicken preservation using coacervates involves encapsulating proteins or antioxidants in a polymer-rich complex coacervate to enhance stability and extend shelf life. Research suggests that coacervates can stabilize proteins and protect against lipid oxidation in chicken meat, potentially increasing its preservation duration. Studies have shown that coacervates formed from specific polypeptides can encapsulate viruses effectively, demonstrating a significant enhancement in stability during accelerated aging studies. Additionally, the use of coacervates in food preservation has shown promising results in inhibiting microbial growth and extending the shelf life of chicken meat without compromising organoleptic parameters. By leveraging the principles of liquid-liquid phase separation and complex coacervation, coacervate-based formulations offer a novel approach to improving chicken preservation.Why is villi height a good marker of intestinal health?5 answers
Villi height is a valuable marker of intestinal health due to its association with crucial functions in the small intestine. Studies have shown that villi height correlates with the absorption capacity of nutrients, impacting overall body weight. Additionally, villi play a significant role in the amplification of the internal surface area of the intestine, enhancing nutrient absorption. Furthermore, alterations in villus morphology are linked to metabolic perturbations, affecting processes like gut microbial metabolism and energy metabolism, which are essential for overall health. The height of villi reflects the state of villus health, with shorter villi being associated with reduced microbial metabolism and muscle metabolism, highlighting the importance of villi height as a marker for intestinal health.How can beta-glucan be analyzed by HPLC?5 answers
Beta-glucan can be analyzed by HPLC (High Performance Liquid Chromatography) to characterize its structure and purity. HPLC analysis of extracted beta-glucan from yeast cells like Saccharomyces cereviseae and Candida albicans shows similarity to standard beta-glucan, with major peaks at 3.22. This method allows for the identification and quantification of beta-glucan components in the samples. Additionally, HPLC can be used to compare beta-glucans from different sources, such as cereals and yeast, to determine their structural similarities and differences. The analysis by HPLC provides valuable insights into the composition and quality of beta-glucan extracts, aiding in research and industrial applications.Can medium chain triglycerides improve digestion?4 answers
Medium-chain triglycerides (MCTs) have shown potential in improving digestion based on research findings. Studies have highlighted that MCTs, when incorporated into structured lipids like EPA-rich medium- and long-chain triacylglycerol (MLCT), can enhance the hydrolysis process during digestion, leading to higher free fatty acid release levels compared to other oils. Additionally, MCTs, commonly used in infant formulas, have been compared to human milk containing medium- and long-chain triacylglycerols (MLCTs), with MLCTs showing a different impact on lipolysis and free fatty acid profiles, potentially affecting infant health. Furthermore, the digestion behaviors of different triglycerides, including MCTs, in dynamic and static simulation models have demonstrated varying digestibility rates, with MCTs exhibiting favorable digestibility characteristics. Overall, incorporating MCTs, especially in structured lipids, may contribute to improved digestion processes.What factors inflence the albumin cocnetration in the dermal interstitial ffluid?5 answers
The concentration of albumin in the dermal interstitial fluid is influenced by several factors. Negatively charged glycosaminoglycans in the extracellular matrix play a significant role in the exclusion of albumin from the interstitial space. Hydration levels also impact the exclusion of albumin, with reduced hydration leading to a diminished effect of negative charges on interstitial exclusion of charged macromolecules. Additionally, the composition of the interstitial matrix, particularly collagen and hyaluronan, affects the exclusion of albumin, with collagen and hyaluronan being responsible for a significant portion of the exclusion volume. These factors collectively contribute to the regulation of albumin concentration in the dermal interstitial fluid.What are the current clinical trials evaluating the safety and efficacy of rezafungin in the treatment of candidiasis?10 answers
Rezafungin is a next-generation echinocandin undergoing evaluation in clinical trials for its safety and efficacy in treating candidiasis, including candidemia and invasive candidiasis (IC). The ReSTORE trial (NCT03667690) is a pivotal Phase 3, global, double-blind, randomized, controlled non-inferiority trial comparing rezafungin administered once weekly to caspofungin given once daily in patients with candidemia and/or IC. This trial demonstrated rezafungin's non-inferiority to caspofungin in terms of global cure at day 14 and all-cause mortality at day 30, highlighting its potential as an effective treatment option for candidiasis.
A sub-analysis of the ReSTORE trial focused on immunocompromised patients, revealing that while immune-compromised status reduced efficacy rates overall, it did not significantly alter the efficacy rate differences between rezafungin and caspofungin, suggesting rezafungin's consistent performance across different patient subgroups. Additionally, the STRIVE trial (Phase 2; NCT02734862) and ReSTORE trial data were analyzed together, providing further evidence of rezafungin's efficacy and safety, with comparable 30-day all-cause mortality rates and safety profiles to caspofungin.
Rezafungin's drug-drug interaction profile has also been extensively studied, showing a low potential for interactions with commonly prescribed medications, which is crucial for the treatment of life-threatening infections in patients who may be on multiple drugs. Furthermore, in vitro studies have supported rezafungin's activity against a wide range of Candida species and other fungi, reinforcing its potential utility in treating candidiasis.
Overall, the clinical trials and studies conducted so far indicate that rezafungin is a promising candidate for the treatment of candidiasis, offering a favorable safety profile, efficacy across multiple Candida species, and a convenient dosing regimen that could improve patient compliance.